Twelve weeks of Gilead Sciences’ Harvoni (ledipasvir/sofosbuvir) cured a respective 93 percent and 95 percent of genotypes 4 and 5 of hepatitis C virus (HCV) in a small trial, MedPage Today reports. Researchers reported on an open-label study of the fixed-dose combination tablet at the 50th International Liver Congress in Vienna, Austria.

The 85 participants were treatment naive or treatment experienced, and either did or did not have cirrhosis. Forty-four of them had genotype 4, and 41 had genotype 5. Sustained virologic response rates 12 weeks after completing therapy (SVR12, considered a cure) were similar across the various patient types.

To read the press release and conference abstract, click here.